Aprea gets 2nd clinical hold in a week, this time for lymphoid malignancy study

A week ago, Aprea Therapeutics was hit with an FDA partial clinical hold on its leading drug, eprenetapopt, in combo with other approved meds in a late-stage myeloid malignancy program.